Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 3
2007 1
2008 1
2009 3
2010 5
2011 8
2012 13
2013 9
2014 6
2015 13
2016 5
2017 5
2018 7
2019 13
2020 28
2021 26
2022 17
2023 20
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. Goetz MP, et al. Among authors: tredan o. J Clin Oncol. 2017 Nov 10;35(32):3638-3646. doi: 10.1200/JCO.2017.75.6155. Epub 2017 Oct 2. J Clin Oncol. 2017. PMID: 28968163 Clinical Trial.
Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
Rugo HS, Bardia A, Marmé F, Cortes J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Pardo PG, Jhaveri KL, Delaney R, Fu O, Lin L, Verret W, Tolaney SM. Rugo HS, et al. Among authors: tredan o. J Clin Oncol. 2022 Oct 10;40(29):3365-3376. doi: 10.1200/JCO.22.01002. Epub 2022 Aug 26. J Clin Oncol. 2022. PMID: 36027558 Clinical Trial.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Gómez Pardo P, Jhaveri KL, Delaney R, Valdez T, Wang H, Motwani M, Yoon OK, Verret W, Tolaney SM. Rugo HS, et al. Among authors: tredan o. Lancet. 2023 Oct 21;402(10411):1423-1433. doi: 10.1016/S0140-6736(23)01245-X. Epub 2023 Aug 23. Lancet. 2023. PMID: 37633306 Free article. Clinical Trial.
Non-genomic signaling of steroid receptors in cancer.
Thiebaut C, Vlaeminck-Guillem V, Trédan O, Poulard C, Le Romancer M. Thiebaut C, et al. Among authors: tredan o. Mol Cell Endocrinol. 2021 Dec 1;538:111453. doi: 10.1016/j.mce.2021.111453. Epub 2021 Sep 11. Mol Cell Endocrinol. 2021. PMID: 34520815 Free article. Review.
Detailed overview on rare malignant ovarian tumors.
Aust S, Eberst L, Tredan O, Rousset-Jablonski C, Treilleux I, Méeus P, Chopin N, Beurrier F, Charreton A, Véronique D, Hallouz A, Coulon A, Ricoeur A, Mastier C, Bouhamama A, Racadot S, Devouassoux-Shisheboran M, Haddad V, Ray-Coquard I. Aust S, et al. Among authors: tredan o. Bull Cancer. 2020 Mar;107(3):385-390. doi: 10.1016/j.bulcan.2020.01.011. Epub 2020 Feb 27. Bull Cancer. 2020. PMID: 32115180 Review.
PRMT5 triggers glucocorticoid-induced cell migration in triple-negative breast cancer.
Noureddine LM, Ablain J, Surmieliova-Garnès A, Jacquemetton J, Pham TH, Marangoni E, Schnitzler A, Bieche I, Badran B, Trédan O, Hussein N, Le Romancer M, Poulard C. Noureddine LM, et al. Among authors: tredan o. Life Sci Alliance. 2023 Aug 3;6(10):e202302009. doi: 10.26508/lsa.202302009. Print 2023 Oct. Life Sci Alliance. 2023. PMID: 37536978 Free PMC article.
Sustainable return to work among breast cancer survivors.
Ruiz de Azua G, Kousignian I, Vaz-Luis I, Di Meglio A, Caumette E, Havas J, Martin E, Martin AL, Querel O, Vanlemmens L, Pistilli B, Coutant C, Cottu PH, Merimeche AD, Lerebours F, Tredan O, Jouannaud C, Levy C, Dumas A, Menvielle G. Ruiz de Azua G, et al. Among authors: tredan o. Cancer Med. 2023 Sep;12(18):19091-19101. doi: 10.1002/cam4.6467. Epub 2023 Aug 21. Cancer Med. 2023. PMID: 37602836 Free PMC article.
[New therapeutic strategies in HER2-positive breast cancer].
Mery B, Toussaint P, Heudel PE, Dufresne A, Carbonnaux M, Vanacker H, Bachelot T, Trédan O. Mery B, et al. Among authors: tredan o. Bull Cancer. 2021 Jun 15:S0007-4551(21)00215-0. doi: 10.1016/j.bulcan.2021.04.015. Online ahead of print. Bull Cancer. 2021. PMID: 34144793 Review. French.
Trends in cancer-targeted antibody-drug conjugates.
Bidard FC, Trédan O. Bidard FC, et al. Among authors: tredan o. Target Oncol. 2014 Mar;9(1):1-8. doi: 10.1007/s11523-013-0302-9. Epub 2013 Nov 13. Target Oncol. 2014. PMID: 24221961 Review.
165 results